PACE-CME.org reports news from EAS 2025.

Episodes 1-6 of 6

First-in-human results of a novel ANGPTL4 inhibitor for lipid lowering
First-in-human results of a novel ANGPTL4 inhibitor for lipid lowering
EAS 2025
First-in-human results of a novel ANGPTL4 inhibitor for lipid lowering
- Ethan Weiss, MD
Effects of bempedoic acid on CV outcomes not modified by add-in lipid-modifying therapy
Effects of bempedoic acid on CV outcomes not modified by add-in lipid-modifying therapy
EAS 2025
Effects of bempedoic acid on CV outcomes not modified by add-in lipid-modifying therapy
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Long-term data of lomitapide in HoFH: 10-year observational data
Long-term data of lomitapide in HoFH: 10-year observational data
EAS 2025
Long-term data of lomitapide in HoFH: 10-year observational data
- Dirk Blom, PhD
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
EAS 2025
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
- Børge G. Nordestgaard, MD, DMSc
Durable reductions in LDL-c with ANGPTL3 siRNA in patients with HoFH
Durable reductions in LDL-c with ANGPTL3 siRNA in patients with HoFH
EAS 2025
Durable reductions in LDL-c with ANGPTL3 siRNA in patients with HoFH
- Prof. Frederick Raal
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
EAS 2025
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
- Stephen Nicholls, FRACP, FACC, FESC, FAHA

Episodes 1-6 of 6

Title

Share on ReachMD